| 0.3675 -0.01 (-2.52%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.63 | 1-year : | 0.79 |
| Resists | First : | 0.54 | Second : | 0.68 |
| Pivot price | 0.4 |
|||
| Supports | First : | 0.33 | Second : | 0.27 |
| MAs | MA(5) : | 0.37 |
MA(20) : | 0.41 |
| MA(100) : | 1 |
MA(250) : | 1.67 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.2 |
D(3) : | 13.8 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 3.79 | Low : | 0.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AEMD ] has closed above bottom band by 13.3%. Bollinger Bands are 71.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.44 - 0.44 | 0.44 - 0.44 |
| Low: | 0.35 - 0.36 | 0.36 - 0.36 |
| Close: | 0.36 - 0.37 | 0.37 - 0.37 |
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Fri, 26 Jul 2024
Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Large Decline in Short Interest - Defense World
Tue, 09 Jul 2024
Aethlon Medical (NASDAQ:AEMD) Stock Crosses Below Two Hundred Day Moving Average of $1.38 - Defense World
Thu, 27 Jun 2024
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update - StockTitan
Thu, 27 Jun 2024
Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript - Seeking Alpha
Thu, 06 Jun 2024
Why Is Aethlon Medical (AEMD) Stock Up 82% Today? - InvestorPlace
Wed, 15 May 2024
Dow Jumps 200 Points; US Inflation Rate Slows In April - Aethlon Medical (NASDAQ:AEMD) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 14 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 751 (K) |
| Shares Short P.Month | 453 (K) |
| EPS | -4.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -57.2 % |
| Return on Equity (ttm) | -117.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.08 |
| PEG Ratio | 0 |
| Price to Book value | 0.16 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|